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represents a novel strategy to reduce gut GVHD by direct
protection of intestinal epitheliumwithout limiting immune
function post-transplant.Table 1
DBY UTY ZFY EIF1AY RPS4Y Any-HY
NMDP
(n[289)
63 (22%) 112 (39%) 22 (8%) 7 (2%) 42 (15%) 143 (49%)
Stanford
(n[90)
20 (22%) 32 (36%) 4 (4%) 1 (1%) 8 (9%) 46 (51%)
Table 2
(NMDP) cGVHD aGVHD Relapse TRM OS
HY-score HR P HR P HR P HR P HR P
0 (n[146) 1 - 1 - 1 　 1 - 1 -
1 (n[75) 1.34 0.15 1.17 0.46 1.22 0.54 0.85 0.44 0.98 0.89
2 (n[39) 1.12 0.65 1.25 0.39 0.63 0.31 0.62 0.078 0.81 0.39
3 to 4
(n[29)
1.32 0.37 1.64 0.064 1.85 0.19 1.3 0.34 1.48 0.09950
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Neddylation is crucial for the degradation of certain proteins.
However its role in regulating T cells is unknown. Neddyla-
tion is mediated by cullin-RING ligase (CRL) protein complex,
an E3 ubiquitin ligase and its critical adapter element, SAG
protein (sensitive to apoptosis gene protein). We explored
the role of SAG and thus neddylation in T cells by utilizing
two different, but complementary approaches, namely,
genetic knock-out and chemical inhibition with small
molecule. The T cell speciﬁc SAG KO animals were generated
by crossing B6 SAGﬂ/ﬂ mice with B6 LCK-Cre mice. The KO
animals were viable. The splenic and thymic analyses
showed no signiﬁcant differences in the numbers of
conventional T cells (Tcons) and Tregs between the KO and
WT animals. In vitro functional analysis of Tcons, however,
revealed that stimulation with either allogeneic splenocytes
or by a-CD3 and a-CD28 antibody, SAG-/- T cells showed
signiﬁcantly decreased proliferation (P<0.002). Phenotypic
analysis following stimulation demonstrated that SAG-/- T
cells showed reduced expression of CD69, CD44 and greater
expression of CD62L when compared to WT-T cells (P<0.04).
The KO-T cells also demonstrated reduced expression of T
effector signature cytokines, IL-17, IFN-g and IL-4. Similar
reduction in proliferation, activation marker expression and
release of cytokines was observed when the WT-T cells were
treated with small molecule inhibitor of neddylation,
MLN4924.
We next determined the in vivo relevance of SAG and
neddylation in Tcons by utilizing the MHC disparate
(B6/BALB/c) model of allogeneic BMT. The BALB/c animals
were lethally irradiated and transplanted with TCD BM from
either syngeneic or allogeneic WT-B6 animals along with
5x105 splenic T cells from either the WT B6 or SAG-/- B6
animals. The allogeneic animals that received SAG-/- T cells
demonstrated markedly reduced clinical GVHD and signiﬁ-
cantly increased survival when compared to those that
received WT-B6 T cells (P<0.001). Similar results were
observed in B6/B6D2F1 model. To further conﬁrm our
results and to determine potential translational application,
we utilized the small molecule MLN4924, once again in the
B6/BALB/c system. The recipient mice were lethally irra-
diated and received 5 doses of MLN4924 (20mg/kg, day-1 to
day +3 of BMT) along with WT-B6 T cells. Mice receiving
MLN4924 demonstrated signiﬁcantly decreased clinical
GVHD and improved survival. Our studies thus demonstrate
that SAG is a novel molecular target for regulating T cell re-
sponses and mitigating GVHD. Furthermore, the clinical
availability of the small molecule, MLN4924, suggests that
this strategy could be tested in carefully designed human
clinical trial for attenuating GVHD.51
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Background: Transplant of male recipients from female
donors (F>M HCT) is well known as a risk factor for devel-
oping chronic graft-versus-host disease (cGVHD).We have so
far suggested that B cell response against minor histocom-
patibility antigens encoded on the Y chromosome, called H-Y
antigens, develops following F>M HCT and associates with
cGVHD. Here, we hypothesize that pre-sensitization to HY-
antigen in a female donor may affect the post-HCT HY-IgG
development and clinical outcomes following F>MHCT. This
study uses our novel HY microarray to determine the prev-
alence and impact of donor HY-IgG.
Methods: Wemeasured IgG against 5 HY antigens (DBY, UTY,
ZFY, EIF1AY, &RBS4Y) in289 femaledonors (age:18-60) of high
resolution 8/8 HLA-matched HCT facilitated by the NMDP be-
tween 1990-2002 and assessed the impact of HY seropositivity
on cumulative cGVHD incidence and other clinical outcomes.
In addition, we studied 90 Stanford adult female donors
and their corresponding male recipients between 2005 and
2012 who survived without relapse for at least 3m post-HCT
and assessed the association of HY-IgG development be-
tween pre- and post-HCT. The cut-off value for seropositivity
was deﬁned as Q3 + 2xIQR, determined from plasma of 60
maledonors. HY-score was deﬁned as the cumulative num-
ber of targeted HY antigens.
Results: Prevalence of HY-IgGs in female donors is shown
in Table1. Half of female donors had at least one of 5
HY-IgG(s). Univariate analyses of NMDP cohort showed that
individual HY-IgGs in female donors were not associated
with cGVHD. Focusing on increasing HY-score, we did not
detect association with cGVHD nor other clinical outcomes
(Table 2). This absence of association was also observed in
Stanford cohort. Further, we were unable to show the
Table 3
DonorDBY DonorUTY DonorZFY DonorEIF1AY DonorRPS4Y
　 - + P - + P - + P - + P - + P
Recipient - 38 7 0.2 31 13 0.28 55 4 0.29 56 1 >0.99 44 5 0.72
post-HCT + 32 13 　 27 19 　 31 0 　 33 0 　 38 3 　
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male recipients (Table 3).
Conclusion: Half of female donors were HY-seropositive, but
there were no enough evidence to suggest that the HY
sensitization can predict clinical outcome. In fact, we pro-
vided little evidence of adoptive HY B-cell immunity transfer.
On-going studies will relate female HY sensitization to parity
and age. The absence of adoptive immune transfer might
raise a concern for the efﬁcacy of donor vaccination strate-
gies to augment GVL beneﬁt.52
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The immunosuppressive function of IL10 producing regula-
tory B cells (Bregs) has been shown in several murine models
of inﬂammation and autoimmune disease. However, there is
a paucity of data regarding the existence of an equivalent
regulatory B cell subset in humans and their relevance in the
pathogenesis of chronic graft-versus-host disease (cGVHD)
remains unknown. Here, we explored the regulatory
properties of peripheral blood (PB)-derived human B cell
subsets and their role in cGVHD. Using intracellular cytokine
staining following in vitro stimulation with CD40 ligand, we
showed that the majority of IL-10 producing B cells in
healthy donors are found within the CD24hiCD38hi transi-
tional and CD19+IgM+CD27+ memory B cell subsets. Sort-
puriﬁed IgM memory and transitional B cells suppressed the
proliferation, as well as the release of IFN-g by CD3/CD28
stimulated CD4+ T cells. The inhibitory effect of IgM memory
and transitional B cells on CD4+ T cell proliferation was cell
dose dependent with the highest suppression was observed
at a ratio of 1:1. These data suggest that human PB transi-
tional and IgM memory B cells are endowed with suppres-
sive function. This suppression was mediated partially via
the provision of IL-10, but not TGF-ß, which we assessed by
antibody blockade experiments. Additionally, the suppres-
sive capacity of the B cell subsets was reversed by the addi-
tion of CD80 and CD86 mAbs. Using transwell experiments,
we further determined that the suppressive function of Bregs
is also partly dependent on direct T cell/B cell contact.
Although blockade of IL-10 and IL-10R, CD80 and CD86 andseparation of B cells and T cells by a transwell membrane
individually did not completely reverse the suppressive
ability of transitional and IgMmemory B cells, a combination
of these factors sufﬁciently reversed the ability of Breg
subsets to suppress CD4+ Tcell proliferation. Thus, analogous
to murine experimental models the suppressive effect of
human Breg cells involves both the release of IL-10 and
co-receptor interaction. Additionally, Breg cells isolated from
patients with cGVHD were refractory to CD40 stimulation
and produced less IL-10 when compared to patients without
cGVHD post-SCT and healthy controls. Likewise, the absolute
number of IL-10 producing B cells was signiﬁcantly lower in
cGvHD patients compared to patients without cGVHD and
healthy controls (p¼0.007), supporting the existence of both
a qualitative and quantitative defect in IL-10 producing
B cells in cGvHD.
Our combined studies provide important new data deﬁning
the phenotype of B cell populations enriched in regulatory
B cells in healthy humans and provide evidence of altered
cellular function within such cells that may impact a broad
range of deﬁciencies in immune regulatory cell function in
cGvHD post transplant patients.
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Background: Commensal gut microbiota have been im-
plicated in initiating and perpetuating intestinal graft versus
host disease (iGVHD), but its role remains controversial. Recent
murine studies have shown that iGVHD results in destruction
of intestinal mucosal immune defenses resulting in expansion
of pro-inﬂammatory bacteria (Enterobacteriaceae, ENTERO),
and by prophylactically treatingmicewith oral antibiotics that
suppress growth of ENTERO, iGVHD was signiﬁcantly
improved1. Furthermore, small-chain fatty acid producing
(SCFA) Clostridia have been shown to induce colonic Treg cells,
to dampen gut inﬂammation, and to cure IBD in mice2. But
theseﬁndingshavenot beenobservedor replicated inhumans.
Methods: Stool samples were collected on a weekly basis
from pediatric allogeneic BMT patients from 7/26/11 e 9/30/
13. Bacterial and fungal gDNA was isolated from fecal spec-
imens. Amplicons for 16S rRNAV4 variable region and fungal
ITS region were generated and sequenced on Roche 454
GS-FLX sequencer and Illumina HiSeq2000 respectively.
Sequencing data was analyzed using QIIME software. The
abundance of speciﬁc intestinal bacterial groups was deter-
mined by qPCR using group-speciﬁc 16S rRNA gene primers.
For patients undergoing intestinal biopsy for suspicion of
iGVHD (abdominal pain, diarrhea), additional pieces of
intestine were obtained for transcription proﬁling experi-
ments using Illumina HumanHT12 V4 Expression BeadChips.
Clinical characteristics (i.e. conditioning regimens, speciﬁc
antibiotic use, immunosuppression, etc) were recorded.
